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ABSTRACT
Objectives: This study was performed to investigate prognostic factors status at smaller tumors in patients with stage 
IB1 cervical cancer (CC) who underwent modified radical or radical hysterectomy.
Matherial and metods: Data from patients diagnosed with CC between January 1995 and January 2017 at the Gynecological 
Oncology Department, Tepecik Training and Research Hospital and Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 
Istanbul, Turkey, were investigated. A total of 182 stage IB1 CC cases were evaluated retrospectively.
Results: Patients were divided into two groups according to tumor size ( < 2 cm and ≥ 2 cm). There were no complications 
associated with the operation in patients with a tumor size < 2 cm. Among patients with a tumor size ≥ 2 cm, however, 0.9% 
(n = 1) developed bladder laceration, 0.9% (n = 1) rectum laceration, and 0.9% (n = 1) pulmonary emboli (P = 0.583). The 
rates of intermediate risk factors (depth of stromal invasion and lymphovascular space invasion) were significantly higher 
and lymph node involvement significantly more frequent in patients with a tumor size ≥ 2 cm. However, there were no 
significant differences in parametrial invasion or vaginal margin involvement between the two groups.
Conclusions: Intermediate risk factors and lymph node metastasis were significantly less frequent in patients with small 
tumors measuring < 2 cm. However, although parametrial involvement and vaginal margin involvement were less common 
in patients with small tumors compared with large tumors (≥ 2 cm), the differences were not significant.
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INTRODUCTION
The standard surgical management for International 
Federation of Gynecology and Obstetrics (FIGO) stage 
IB1 cervical cancer (CC) is radical hysterectomy and bilateral 
pelvic lymph node (LN) dissection. CC usually spreads in 
a lateral direction along the parametrium and vagina, uterine 
corpus, and LNs via straight local spread or permeation of 
tumor emboli into the lymphovascular space [1]. Radical 
resection of the parametrial tissue is the major surgical 
intervention for CC. The overall survival rate of patients with 
early stage CC treated by radical hysterectomy is excellent [1]. 
Parametrectomy is the major reason for postoperative 
complications, including lower urinary system dysfunction, 
sexual dysfunction, and anorectal motility disorders, which 
are attributed to partial denervation of the autonomic nerve 
supply to the pelvic organs throughout parametrial resection 
[1–3]. Recent studies have questioned the effectiveness and 
safety of radical hysterectomy considering the high rate 
of long-term postoperative complications. To prevent this 
morbidity, some researchers have attempted to determine 
methods of preoperatively identifying patients with early 
stage CC at low risk who may benefit from a less radical 
procedure without adversely affecting the survival rate.
The FIGO clinical staging system does not include 
assessment of LN status, microscopic parametrial 
involvement, vaginal margin involvement, depth of stromal 
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invasion (DOI), or lymphovascular space invasion (LVSI) [4–6]. 
Parametrial involvement, vaginal margin involvement, and 
LN metastasis are considered high risk factors associated 
with an increased recurrence rate and decreased survival 
rate [5]. DOI and LVSI are intermediate risk factors.
Here, we compare the incidences of intermediate and 
high risk factors in stage IB1 CC patients with small and large 
tumors (< 2 cm and ≥ 2 cm, respectively). The main purpose 
of this study was performed to investigate prognostic factors 
status at smaller tumors in patients with stage IB1 cervical 
cancer (CC) who underwent modified radical or radical 
hysterectomy.
MATERIAL AND METHODS
Data from patients diagnosed with CC between Janu-
ary 1995 and January 2017 at the Gynecological Oncology 
Department, Tepecik Training and Research Hospital and 
Bakirkoy Dr. Sadi Konuk Training and Research Hospital, were 
investigated. A total of 182 cases with stage IB1 CC were 
evaluated retrospectively. All operations were performed by 
expert gynecological oncologists. The study was approved 
by the local ethics committees of the participating institu-
tions and was conducted in accordance with the ethical 
standards of the Declaration of Helsinki.
Patients with FIGO stage IB1 CC who underwent radical 
or modified radical hysterectomy and pelvic ± paraaortic 
LN dissection were included in the study. Patients with 
local advanced stage CC and those who had undergone 
type 1 hysterectomy or surgery without lymphadenectomy 
were excluded. A flowchart of the recruitment of the study 
patients is shown in Figure 1. Staging was performed 
according to the FIGO 2009 clinical staging system by 
examination under general anesthesia, and patients were 
evaluated using imaging modalities. The patients completed 
follow-up evaluations every 3 months for the first 2 years, 
every 6 months for the next 3 years, and annually thereafter. 
Computed tomography or magnetic resonance imaging was 
performed annually.
Clinical data were obtained from the patients’ files. Patient 
age, menopausal status, type of surgery, adjuvant therapy, 
disease-free survival, and overall survival were investigated. 
Surveillance consisted mainly of a physical examination 
and questioning the patients about their symptoms. Tumor 
recurrence was confirmed via clinical pelvic exam or imaging 
studies during a regular visit or following the occurrence 
of symptoms, such as vaginal spotting or abdominal 
discomfort. All surgical specimens were evaluated by 
specialized gynecological pathologists. Tumor size, DOI, 
LVSI, LN status, vaginal margin status, and parametrial 
involvement were analyzed in accordance with the 
pathology reports. The numbers of pelvic and paraaortic 
LNs and LN involvement were evaluated from the pathology 
reports. DOI was defined as the measurement of the tumor 
from the epithelial-stromal junction of the adjacent most 
superficial epithelial papilla to the deepest point of invasion. 
LVSI was defined as the presence of tumor cells inside the 
capillary lumens of either the lymphatic or microvascular 
drainage systems within the primary tumor. 
Radical hysterectomy (RH), (type 3 or type C2) con-
sisted of removal of the uterus and adjacent parametrium 
to its most lateral extent, along the paracolpium and the 
upper portion of the vagina and the proximal uterosacral 
ligaments. Modified radical hysterectomy (type 2 or type B) 
included removal of the uterus, cervix, upper one fourth 
of the vagina, 1 cm ventral parametrium, 1–1.5 cm lateral 
parametrium, and 1–2 cm dorsal parametrium. Pelvic lym-
Figure 1. Flowchart of patient recruitment into the study 
Adj — adjuvant; RT — radiotherapy; CRT — chemoradiotherapy; H — hysterectomy; LND — lymph node dissection
Type 2/3 H with LND (n = 182)
Study group
Cervical cancer (n = 884)
Stage I (n = 62) IB1 (n = 217) IB2 (n = 97) IIA (n = 59) IIB–IVB (n = 449)
Operation (n = 40) Operation + Adj. therapy (n = 158) Primary RT/CRT (n = 19)
Type 1 H (n = 12) Type 2/3 H without LND (n = 4)
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phadenectomy consisted of removal of the lymphatic tis-
sue over the external and common iliac vessels and in the 
obturator fossa. Paraaortic LN dissection was performed by 
removal of the lymphatic tissue over the inferior vena cava 
and aorta, beginning at the bifurcation and proceeding to 
the inferior mesenteric artery if necessary [7]. Pelvic LN dis-
section was performed all patients. Para-aortic LN dissection 
was performed in 157 patients (86.3%). The process was ap-
plied patients who a bulky LN and/or suspicious appearance 
in the paraaortic LN area.
Disease-free survival was defined as the interval from 
the date of primary surgery to detection of recurrence or 
the latest observation. Overall survival was defined as the 
interval from the date of primary surgery to death or the latest 
observation. Survival was analyzed using the Kaplan–Meier 
method, and the results were compared using the log-rank 
test. Logistic regression analysis was used to define the 
predictive factors. The χ2 test and Student’s t test were used 
for unpaired data comparisons. All statistical analyses were 
performed using MedCalc software (version 14.0 for Windows; 
MedCalc Software, Mariakerke, Belgium). In all analyses, 
P < 0.05 was considered to indicate statistical significance.
RESULTS
Patients were divided into two groups according to tu-
mor size (< 2 cm and ≥ 2 cm). The clinical and demographic 
characteristics of the patients are shown in Table 1, and 
the treatment options used as primary therapy are shown 
in Table 2. The mean DFS was calculated as 89.2 months 
(95% CI = 72.4–105.9) for tumors < 2 cm and 78.3 months 
(95% CI = 67.6–89.1) for ≥ 2 cm tumors in stage IB1 cer-
vical cancer who underwent type B or C2 hysterectomy 
(P = 0.256). The mean DFS was calculated as 94.3 months 
(95% CI = 77.7–110.8) for tumors < 2 cm and 79.6 months 
(95% CI = 68.9–90.3) for ≥ 2 cm tumors (P = 0.124).
Patients with a tumor size < 2 cm did not develop com-
plications from the operation. However, a number of compli-
cations were observed in patients with a tumor size ≥ 2 cm, 
including bladder laceration (0.9%, n = 1), rectum laceration 
(0.9%, n = 1), and pulmonary emboli (0.9%, n = 1) (P = 0.583). 
In patients with tumors < 2 cm, recurrence was noted in the 
vagina (5.6%, n = 4), vertebrae (2.8%, n = 2), pelvic region 
(1.4%, n = 1), and multiple organs (1.4%, n = 1). Patients 
with tumors ≥ 2 cm showed multiple organ metastases 
(2.7%, n = 3) and recurrence in the vagina (1.8%, n = 2), 
pulmonary system (0.9%, n = 1), liver (0.9%, n = 1), and 
pelvis (0.9%, n = 1).
Patients with tumors < 2 cm and those with tumors ≥ 2 cm 
were compared according to the presence of intermediate 
and high risk factors (Tab. 3). The rates of intermediate risk 
factors were significantly higher in patients with a tumor 
size ≥ 2 cm compared with < 2 cm. LN involvement was 
significantly more frequent in patients with tumors ≥ 2 cm, 
but there were no significant differences in parametrial 
invasion or vaginal margin involvement between the two 
Table 1. Clinical and demographic patient characteristics
Tumor size 
 < 2 cm 
(n = 71)
Tumor size 
 ≥ 2 cm 
(n = 111)
P
Tumor size, mean ± SD 0.9 ± 0.4 3.0 ± 0.7  < 0.001
Age, mean ± SD 47.0 ± 10.6 48.8 ± 8.9 0.208
Postmenopausal state [%] 36 (50.7) 55 (49.5) 0.879
Hemoglobin, mean ± SD 12.1 ± 1.6 12.3 ± 1.5 0.620
Pelvic LN, mean ± SD 28.0 ± 12.2 26.8 ± 12.1 0.538
Paraaortic LN, mean ± SD 9.4 ± 6.8 10.0 ± 7.2 0.655
Histological type [%]
— SCC
— AC
— ASC
52 (73.2)
16 (22.5)
3 (4.3)
82 (73.9)
18 (16.2)
11 (9.9)
0.315
Recurrence [%] 8 (11.3) 8 (7.2) 0.345
DFS, 3 years [%] 91.2 96.2 0.437
DFS, 5 years [%] 89.3 93.5 0.437
OS, 3 years [%] 91.4 93.1 0.720
OS, 5 years [%] 85.5 89.0 0.720
LN — lymph node; SCC — squamous cell carcinoma; AC — adenocarcinoma; 
ASC —adenosquamous cell carcinoma; DFS — disease free survival; OS 
— overall survival; SD —standard deviation
Table 2. Treatment options given as primary therapy
Tumor size 
 < 2 cm 
(n = 71)
Tumor size 
 ≥ 2 cm 
(n = 111)
P
Primary therapy [%]
— Surgery
— Surgery + adjuvant RT
— Surgery + adjuvant CRT
39 (54.9)
19 (26.8)
13 (18.3)
17 (15.3)
48 (43.2)
46 (41.5)
 < 0.001
Surgery type [%]
— Type 2 H PPLND
— Type 2 H BSO PPLND
— Type 3 H PPLND
— Type 3 H BSO PPLND
2 (2.8)
5 (7.0)
6 (8.5)
58 (81.7)
0 (0)
6 (5.4)
4 (3.6)
101 (91.0)
0.133
IRT, Gy 6–9.25 Gy 5–9.25 Gy 0.758
ERT, Gy 36–54 45–54 0.812
CT [%]
— Cisplatin
— Cisplatin + Ifosfamide
— Carboplatin
— Carboplatin + Paclitaxel
12 (92.4)
0
0
1 (7.6)
43 (93.7)
2 (4.2)
1 (2.1)
0
0.008
RT — radiotherapy; CRT — chemoradiotherapy; H BSO PPLND 
— hysterectomy + bilateral salpingo-oophorectomy + pelvic paraaortic 
lymph node dissection; IRT — internal radiotherapy; ERT — external 
radiotherapy; CT — chemotherapy
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groups. The other risk factor is histological type that is not 
in the table. Nineteen (26.8%) of the patients with small 
tumors (< 2 cm) had histological type of non-squamous cell 
carcinoma. Similarly, twenty-nine (26.1%) of patients with 
large tumors (≥ 2 cm) had non-squamous cell carcinoma. 
No significant difference was found (P = 0.925).
LN involvement was higher in patients with large 
tumors. Pelvic lymph node involvement was found in 7 (9.9%) 
patients with small tumors and in 26 (23.4%) of patients with 
large tumors (P = 0.021). However, the number of patients 
with paraartic lymph node metastases was very low [2 (1.8%) 
patients in large tumors, 0 patients in small tumors; P = 0.283].
Subgroup analysis was performed according to patients 
with a tumor size < 2 cm, DOI < 1/2 (< 5 mm), and LVSI 
negativity (n = 33) versus patients with a tumor size ≥ 2 cm 
or presence of any intermediate risk factors independent 
of tumor size (n = 149). Patients with no intermediate risk 
factors with a tumor size < 2 cm had lower rates of LN 
involvement than did patients with a tumor size ≥ 2 cm or 
presence of any intermediate risk factors (3.0% vs. 21.5%, 
respectively; P = 0.013). However, there were no significant 
differences in parametrial involvement (3.0% vs. 4.7%, 
respectively; P = 0.672) or vaginal margin involvement (3.0% 
vs. 5.4%, respectively; P = 0.575).
DISCUSSION
This study was performed to compare the incidences of 
intermediate and high risk factors in stage IB1 CC patients 
with a small versus large tumor size (< 2 cm vs. ≥ 2 cm). Al-
though type III and type C RH have been shown to have excel-
lent prognoses in terms of survival, the significant morbidity 
related to the procedure adversely affects patients’ quality of 
life. Therefore, there is growing interest in the use of less radi-
cal surgical procedures to replace type III and type C RH [1].
LVSI involvement [8, 9], DOI > 1/2 [8, 10], parametrial mi-
croinvasion [1, 8, 11–13], LN metastasis [8, 10, 12], and vagi-
nal margin involvement [12] are significantly more frequent 
in stage IB1 CC patients with a tumor diameter ≥ 2 cm than in 
those with smaller tumors. Although parametrial invasion 
[10] and positive vaginal margin involvement [5, 8, 10] were 
more frequently associated with tumors ≥ 2 cm in diameter, 
some studies indicated no significant differences according 
to tumor size. Studies evaluating microinvasion observed 
during radical resection of the parametrium, which is the 
primary aim of radical surgery, showed that tumor size was 
an independent predictor of parametrial spread according 
to regression analyses [1, 3, 14]. In our study, parametrial 
invasion was only detected in eight patients. We found less 
parametrial invasion in patients with small tumors, but there 
was no significant difference between the two groups. This 
may have been because the incidence of parametrial inva-
sion in our group was lower than that in other studies. The 
rates of intermediate risk factors and LN involvement were 
significantly lower in patients with small tumors (< 2 cm) 
compared with large tumors (≥ 2 cm). Consistent with the 
literature, although vaginal margin involvement was found 
more frequently in patients with large tumors in the present 
study, this difference was not significant. 
There have been a number of recent reports regarding the 
application of more conservative surgical procedures in place 
of radical hysterectomy, which negatively affects quality of 
life, without increasing the risk of recurrence. The primary aim 
of avoiding radical surgery is to prevent complications, such as 
ureteric injury, fistulas, blood loss, and urinary dysfunction. In 
our cohort, the rates of LN metastasis, parametrial involvement, 
and vaginal margin involvement were all approximately 3.0% 
in patients with small tumors who did not have any of the 
intermediate risk factors evaluated. Patients with a low risk of 
parametrial spread or disease recurrence may be candidates 
for less radical surgical procedures. In comparison with CC 
without parametrial involvement, patients with parametrial 
involvement had larger tumors (P < 0.04), higher incidence 
of LVSI (P < 0.001), greater depth of invasion (P < 0.001), and 
greater rate of pelvic LN metastases (P < 0.001) [15]. To detect 
parametrial spread, it may be possible to investigate factors 
such as tumor size, DOI, and LVSI, because these factors can be 
evaluated preoperatively by pathological examination of 
conization specimens. It is important to identify appropriate 
candidates and manage them in a suitable way. One of the 
most important factors responsible for recurrence is tumor 
size. Tumors ≥ 2 cm in size have an elevated risk of recurrence 
compared with tumors < 2 cm in size (12.5% vs. 1.2%) [16]. 
Table 3. Risk factors according to tumor size
Tumor size
 < 2 cm (n = 71)
Tumor size
 ≥ 2 cm (n = 111) P
Intermediate risk factors DOI, deep 1/2 [%]LVSI [%]
25 (35.2)
17 (23.9)
58 (52.3)
46 (41.4)
0.024
0.016
High risk factors
LN involvement [%]
PI [%]
VM involvement [%]
7 (9.9)
2 (2.8)
2 (2.8)
26 (23.4)
6 (5.4)
7 (6.3)
0.021
0.406
0.290
DOI — depth of stromal invasion; LVSI — lymphovascular space invasion; LN — lymph node; PI Īparametrial invasion; VM — vaginal margin
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Less radical operations, such as type I hysterectomy with LN 
dissection, may be viable alternatives for low-risk candidates 
with clinical factors such as small tumor size, negative LN, 
superficial invasion, and negative LVSI. It is important to note 
that even with conservative management, all patients should 
routinely undergo sentinel node identification or complete 
pelvic lymphadenectomy [17]. Additional prospective 
studies are needed to determine whether patients with stage 
IB1 lesions can be treated with less radical surgical procedures. 
This study had several limitations. First, it was 
a retrospective analysis of patients from various 
institutions. Due to the retrospective nature of the study, 
the presence of other potentially confounding variables, 
such as selection and recall bias, that may have affected 
our results, could not be excluded. Second, the procedures 
were performed by many different surgeons (gynecological 
oncologists). Third, all surgical specimens were evaluated 
by many different gynecological pathologists. In addition, 
there was no standardized pathological slide review. Despite 
these limitations, the similarities in the demographic 
characteristics of the study population and analysis by 
expert pathologists increased the validity of our results and 
mitigated these weaknesses. Moreover, the availability of 
abundant follow-up data increased the validity of the results.
In conclusion, intermediate risk factors and LN 
metastasis were found to be significantly less frequent 
in patients with a small tumor size. Although the rates of 
parametrial involvement and vaginal margin involvement 
were lower in patients with small tumors than in those with 
large tumors, the differences were not significant. Although 
the results were not highly reliable because of the small 
number of patients included in our study, the surgical 
procedure was individualized in patients with small tumors 
who had a negative LVSI and superficial DOI according to 
the preoperative pathology reports. 
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